Geron Gets Green Light To Test Embryonic Stem Cell Therapy On Humans
This article was originally published in The Pink Sheet Daily
Executive Summary
After being delayed since May, Geron’s 21,000-page application clears overnight in the first week of the Obama administration.
You may also be interested in...
Geron Restructuring Sours Investors As Company Bets On Cancer
The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.
Geron Looks For Partnerships With Revised Leadership Team
Longtime CFO David Greenwood, who led the biotech's 1996 IPO, becomes president and interim CEO of Geron, whose human embryonic stem cell program is back on track.
Geron Looks For Partnerships With Revised Leadership Team
Longtime CFO David Greenwood, who led the biotech's 1996 IPO, becomes president and interim CEO of Geron, whose human embryonic stem cell program is back on track.